

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandra, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/701,939	11/04/2003	Guohua Chen	ARC 3307 US R1	5013
20222098 EDGAR R. CATAXINOS TraskBrit, PC P. O. Box 2550 Salt Lake City, UT 84110			EXAMINER	
			KENNEDY, SHARON E	
			ART UNIT	PAPER NUMBER
	,		1615	
			MAIL DATE	DELIVERY MODE
			02/22/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Response to Rule 312 Communication

a) XI entered

Application No.	Applicant(s)	
10/701,939	CHEN ET AL.	
Examiner	Art Unit	П
Sharon F. Kennedy	1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. The amendment filed on <u>08 February 2008</u> under 37 CFR 1.312 has been considered, and has been:

٠٠, ٢	one of
b) 🔲	entered as directed to matters of form not affecting the scope of the invention.
c) 🗆	disapproved because the amendment was filed after the payment of the issue fee. Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.
d) 🔲	disapproved. See explanation below.
e) 🔲	entered in part. See explanation below.
	ding the amendments to the specification, paragraph [0146], the deleted drugs are already cited previously in the aph. It is evident that the deletion eliminates a duplicate cite and is not new matter.

Primary Examiner, Art Unit 1615